placeholder image
J. B. Buse uri icon qr icon All authors
About me
Publications
selected publications
Journal Article
  • Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial
    JAMA. 2021
  • The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin
    Diabetes care. 2021
  • Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial
    Diabetes, Obesity & Metabolism. 2018
  • Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes
    JAMA cardiology. 2017
  • Liraglutide and renal outcomes in type 2 diabetes
    New England Journal of Medicine. 2017
  • Liraglutide and cardiovascular outcomes in type 2 diabetes
    New England Journal of Medicine. 2016
  • Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes
    Diabetes care. 2016
  • Insulin dose and cardiovascular mortality in the ACCORD Trial
    Diabetes care. 2015
  • LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
    Diabetes, Obesity & Metabolism. 2015
  • Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    Diabetologia. 2015
  • Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    Diabetes care. 2015
  • LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial
    Pancreas. 2014
  • Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial
    Diabetes care. 2014
  • Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial
    American Heart Journal. 2013
  • Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes
    Diabetes care. 2012
  • Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
    Diabetologia. 2012
  • Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Diabetologia. 2012
  • Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants
    Diabetes care. 2012
  • Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience
    Diabetes Technology & Therapeutics. 2011
  • Long-term effects of intensive glucose lowering on cardiovascular outcomes
    New England Journal of Medicine. 2011
  • Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase
    Diabetes care. 2011
  • Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
    Annals of Internal Medicine. 2011
  • Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes
    New England Journal of Medicine. 2010
  • Effects of combination lipid therapy in type 2 diabetes mellitus
    New England Journal of Medicine. 2010
  • Effects of intensive blood-pressure control in type 2 diabetes mellitus
    New England Journal of Medicine. 2010
  • Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits
    Diabetes care. 2010
  • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    Lancet (London, England). 2009
  • Effects of intensive glucose lowering in type 2 diabetes
    New England Journal of Medicine. 2008
  • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
    Lancet (London, England). 2008
  • A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Diabetes care. 2005
  • Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes
    Current Medical Research and Opinion. 2004
  • The insulin resistance syndrome and coronary artery disease
    Coronary Artery Disease. 2003
  • Contact
    full name
  • J. B. Buse
  • Quick Info
     
    Collaboration